BioCryst Pharma (BCRX) Commences Public Offering of Common Stock and Pre-Funded Warrants

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that it is offering to sell $100 million of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock in an underwritten public offering. As part of this offering, BioCryst intends to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount equal to up to 15% of the securities offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

J.P. Morgan and Piper Sandler are acting as joint book-running managers for the offering.

All of the securities to be sold in the offering are being sold by BioCryst, with the proceeds to be used for general corporate purposes, which may include, but are not limited to, worldwide development, manufacturing, regulatory, pre-launch and commercial activities for the prophylactic berotralstat (BCX7353) program in the United States and European Union; advancement of the worldwide development, manufacturing, regulatory and clinical activities for BCX9930 for complement-mediated diseases; post-approval commitments for RAPIVABTM/ALPIVABTM; and capital expenditures and other general working capital needs.

You May Also Be Interested In

• Venu Holding enters $250 million at-the-market stock offering agreement
• SU Group Holdings (SUGP) files for 38.32M share offering by sellng stockholders
• Freedom Holding launches $300 million common stock offering